Loading organizations...
§ Private Profile · Cambridge, MA, USA
A biotech startup developing next-generation non-viral gene therapies using REGENT™ technology for rare and broad diseases.
Carmine Therapeutics has raised $5.0M across 1 funding round.
Key people at Carmine Therapeutics.
Carmine Therapeutics has raised $5.0M in total across 1 funding round.
Carmine Therapeutics is a Cambridge, Massachusetts-based biotechnology company that develops next-generation, non-viral gene therapies utilizing proprietary extracellular vesicle technology derived from human red blood cells. The firm's REGENT platform addresses the manufacturing and immunogenicity limitations of traditional viral vectors by enabling significantly larger payload capacities and potential repeat dosing for patients across a broad spectrum of diseases. Operating with an additional research presence in Singapore, the enterprise secured a $900 million research and development collaboration agreement with Takeda to discover and commercialize novel treatments for rare genetic conditions. The private startup is financially backed by venture incubator EVX Ventures and is currently directed by Chief Executive Officer Don Haut alongside board member Elan Ezickson. Carmine Therapeutics was founded in 2019 by Harvey Lodish, Jiahai Shi, Minh Le, XQ Lin, and Tenzin Gocha.
Carmine Therapeutics has raised $5.0M in total across 1 funding round.
Carmine Therapeutics's investors include Madhu Natarajan.
Carmine Therapeutics has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Other Equity in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 30, 2020 | $5M Venture Round | Madhu Natarajan | — | Announced |
Key people at Carmine Therapeutics.
Carmine Therapeutics is a biotechnology company developing next-generation non-viral gene therapies using red blood cell extracellular vesicles (RBCEVs) to deliver genetic medicines.[1][3][4] Their platform addresses limitations of viral-based therapies, such as immunogenicity, limited transgene capacity, and manufacturing challenges, by leveraging RBCEVs' biocompatibility, ready availability from blood units, and modularity for nucleic acid loading and surface modification.[1][6][7] The company serves patients with unmet medical needs in genetic diseases, aiming to make therapies broadly accessible through scalable, non-immunogenic delivery.[1][5]
Headquartered in Cambridge, Massachusetts, as an Esco Ventures X (EVX) company, Carmine focuses on pioneering RBCEV-based gene therapies with strong early intellectual property, including a granted patent as the first to harness RBCEVs for this purpose.[3][7] Growth momentum stems from their foundational 2018 Nature Communications publication on efficient RNA delivery via RBCEVs and recent launch announcements, positioning them for pipeline advancement.[1]
Carmine Therapeutics emerged from Esco Ventures X (EVX), a venture builder launching the company to pioneer RBCEV-based gene therapies.[3][5] The core technology builds on a 2018 Nature Communications paper demonstrating efficient RNA drug delivery using RBCEVs, authored by researchers including Jiahai Shi and Minh T. N. Le, highlighting RBCEVs' natural production by red blood cells lacking genetic material.[1]
Launched via EVX announcement, Carmine capitalized on this preclinical validation to develop lab-produced EVs from red blood cells for novel gene therapies.[5] Pivotal early traction includes securing a granted patent, establishing them as the world's first company using RBCEVs as gene therapy vehicles, which humanizes their origin as a science-driven spinout addressing viral therapy gaps.[7]
Carmine's platform stands out in gene therapy through these key advantages:
These features enable non-viral alternatives that overcome viral limitations, with strong biotech ecosystem ties via EVX.[3]
Carmine rides the gene therapy revolution, shifting from viral vectors (e.g., AAVs) hampered by immunogenicity, payload limits, and high costs toward non-viral platforms like extracellular vesicles (EVs).[1][4] Timing aligns with surging demand for accessible genetic medicines amid rising rare disease diagnoses and CRISPR advancements, where scalable delivery is critical.[1]
Market forces favor them: blood-derived RBCEVs tap abundant, low-cost sources, reducing barriers versus cell therapy manufacturing, while EV interest grows (e.g., post-2018 validations).[1][5] As an EVX portfolio company in Cambridge's biotech hub, Carmine influences the ecosystem by de-risking non-viral gene delivery, potentially accelerating therapies for unmet needs and inspiring EV platforms beyond genetics.[3][7]
Carmine is poised to advance RBCEV therapies into preclinical and clinical pipelines, leveraging their patent and modularity for diverse genetic diseases.[4][7] Key trends like non-viral delivery scale-up and EV standardization will shape their path, amplified by biotech funding in accessible gene meds.[1]
Their influence may evolve as first-mover, partnering for commercialization or expanding to systemic delivery, solidifying non-viral gene therapy's role in making treatments as routine as blood draws—directly advancing their vision of broad accessibility.[1][5]